Literature DB >> 2662481

An evaluation of the cyclosporine and metabolites whole blood TDx assay.

T J Schroeder1, A J Pesce, L L Hindenlang, P A Mauser, D L Ruckrigl, M L Weibel, G Wadih, M R First.   

Abstract

The new Abbott TDx cyclosporine and metabolites fluorescent polarization immunoassay procedure provides a 20-min sample turn-around time, using 50 microliters of sample for the analysis of cyclosporine in whole blood. A precipitation agent and a lysing agent are utilized as a pretreatment step. The range of the whole blood assay is from 0 to 2,000 ng/ml, with a sensitivity of 50 ng/ml. Precision studies at 3 control levels provided coefficients of variation of 2.1-4.8% for both assays. In order to compare this assay with the currently used Sandoz polyclonal radioimmunoassay (RIA) method. 200 whole blood samples were obtained from 20 renal, cardiac, and hepatic transplant recipients. The mean whole blood cyclosporine concentrations for samples above the sensitivity level were as follows: TDx 754 ng/ml (+/- 31) and RIA 619 ng/ml (+/- 22). Blood TDx levels correlated strongly with RIA levels, with a regression coefficient of r = 0.915. This new assay provides reliable blood cyclosporine concentrations that correlate well with RIA measurements. This assay offers rapid sample turn-around times, making same-day results for outpatient drug monitoring possible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2662481

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  2 in total

1.  Bile and blood ratios of cyclosporin and its metabolites in patients on continuous infusion during the first three weeks after liver transplantation.

Authors:  D Debruyne; D Samba; J Lacotte; J Tartière; J P Deshayes; P Segol; H Bricard; M Moulin
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 2.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.